首页> 外国专利> MKRN1 Pharmaceutical composition for metabolic disease comprising expression or activity inhibitor of MKRN1 as an active ingredient

MKRN1 Pharmaceutical composition for metabolic disease comprising expression or activity inhibitor of MKRN1 as an active ingredient

机译:MKRN1用于代谢疾病的药物组合物,其包含作为活性成分的MKRN1的表达或活性抑制剂

摘要

The present invention relates to a pharmaceutical composition for the prevention and treatment of metabolic diseases, which contains an expression or activity inhibitor of MKRN1 as an active ingredient. The MKRN1 of the present invention is an E3-linking enzyme (E3-linking enzyme) for ubiquitinating AMPKα, ligase, which degrades AMPK protein. Thus, inhibition of MKRN1 expression can restore AMPK expression and activity levels. In addition, since it can exhibit an improvement effect on obesity, diabetes and fatty liver by knockout of MKRN1 expression and knockout of MKRN1 in a mouse model in which obesity, diabetes and fatty liver are induced by high fat diet, the expression or activity of MKRN1 of the present invention An inhibitor can be usefully used as an effective ingredient of a composition for preventing and treating metabolic diseases.
机译:本发明涉及用于预防和治疗代谢疾病的药物组合物,其包含MKRN1的表达或活性抑制剂作为活性成分。本发明的MKRN1是用于使降解AMPK蛋白的AMPKα连接酶泛素化的E3连接酶(E3连接酶)。因此,抑制MKRN1表达可以恢复AMPK表达和活性水平。另外,由于在高脂饮食诱导肥胖,糖尿病和脂肪肝的小鼠模型中,通过敲除MKRN1表达和敲除MKRN1,可以显示出对肥胖,糖尿病和脂肪肝的改善效果,因此,其表达或活性可以通过增加MKRN1的表达来发挥。本发明的MKRN1抑制剂可以有效地用作预防和治疗代谢疾病的组合物的有效成分。

著录项

  • 公开/公告号KR101925020B1

    专利类型

  • 公开/公告日2018-12-04

    原文格式PDF

  • 申请/专利权人 연세대학교 산학협력단;

    申请/专利号KR20170051624

  • 发明设计人 송재환;이민식;

    申请日2017-04-21

  • 分类号A61K48;A23L33/13;

  • 国家 KR

  • 入库时间 2022-08-21 11:52:02

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号